89 results
PRE 14A
LRMR
Larimar Therapeutics Inc
12 Apr 24
Preliminary proxy
6:06am
”), a pharmaceutical company of Johnson & Johnson, Inc. (“Johnson & Johnson”) from April 2018 to April 2022, where he led a global, 175-person R&D department
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
11 Mar 24
Other Events
4:09pm
of Philadelphia (CHOP) Professor in the Division of Human Genetics, Department of Pediatrics at University of Pennsylvania Perelman School of Medicine Marni J. Falk
8-K
EX-1.1
qsopie
16 Feb 24
Entry into a Material Definitive Agreement
4:06pm
424B5
0vzjl 7te
14 Feb 24
Prospectus supplement for primary offering
5:08pm
424B5
pm2k2bona mmb
13 Feb 24
Prospectus supplement for primary offering
4:46pm
8-K
EX-99.2
3kd9ioeq852xd 6pu
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.2
015vp 7ois37n
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.1
0f4f1n qdqshrzm
14 Aug 23
Other Events
8:00am
8-K
EX-99.1
73rf np1i
1 Jun 23
June 2023 Larimar Therapeutics Corporate Presentation
4:06pm
8-K
EX-99.2
yz1 xdwcgjcf5g5ojf
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
EX-99.1
3efdf3nvv os
20 Oct 22
October 2022 Larimar Therapeutics Corporate Presentation
8:11am
8-K
EX-1.1
8ukzyl2iwwj
14 Sep 22
Entry into a Material Definitive Agreement
9:01am
8-K
EX-99.2
5kuvamek9mol idur
14 Sep 22
Other Events
7:05am
8-K
EX-99.2
rgw0ru5cwis h94c3
11 Aug 22
Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022
4:13pm
8-K
EX-99.2
jdiag t6o
12 May 22
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
7:12am